Printer Friendly

EMBREX REGISTRATION STATEMENT DECLARED EFFECTIVE

 EMBREX REGISTRATION STATEMENT DECLARED EFFECTIVE
 RESEARCH TRIANGLE PARK, N.C., Nov. 7 /PRNewswire/ -- Embrex Inc.


(NASDAQ: EMBX) today announced that the Securities and Exchange Commission has declared effective the registration statement for its initial public offering of 2.2 million shares of common stock and the same number of redeemable warrants, underwritten by a national syndicate led by Josephthal Lyon & Ross Incorporated of New York. The public offering prices are $8.50 per share and $.10 per warrant.
 Embrex expects to receive net proceeds from the offering of approximately $16.4 million.
 Embrex common stock (EMBX) and redeemable warrants (EMBXW) have been accepted for trading on the NASDAQ National Market System. A prospectus may be obtained from Josephthal Lyon & Ross Incorporated, 6 East 43rd St., New York, N.Y. 10017.
 Embrex develops and has recently begun marketing proprietary bioscience and bioengineering-based products to increase the productivity and profitability of the poultry industry.
 -0- 11/7/91
 /CONTACT: Randall Marcuson of Embrex, 919-941-5185, or Douglas Johnson of GreenTree Communications, 800-428-8796, for Embrex/
 (EMBX) CO: Embrex, Inc. ST: North Carolina IN: MTC SU: FC-OS -- NY048 -- 2197 11/07/91 12:02 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 7, 1991
Words:190
Previous Article:ALEXANDER & ALEXANDER SERVICES, ALEXANDER & ALEXANDER EUROPE AND REED STENHOUSE COMPANIES DECLARE REGULAR QUARTERLY DIVIDENDS
Next Article:ADVANCED MAGNETICS, INC. REPORTS FISCAL 1991 RESULTS
Topics:


Related Articles
EMBREX'S NEW INOVOJECT SYSTEM COMPLETES SECOND PERFORMANCE SERIES
EMBREX REPORTS FOURTH QUARTER AND YEAR-END RESULTS
In Ovo Infectious Bursal Disease Vaccine Approved By USDA
Multi-Hatchery Trials of 20 Million Broilers Show Bursaplex Improves Key Production Parameters
Embrex Names Joseph O'Dowd Director of Latin America
Embrex Second-Quarter Net Income Up 45% Due To Continued Revenue Growth
Embrex's In Ovo Vaccine, Bursaplex(TM), Receives Regulatory Approval From Thailand
Embrex Statement Regarding Avian Influenza.
Embrex Names Jose Antonio Varona General Manager of Mexican Operations; Varona Brings Expertise in Poultry Production, Vaccines and Business.
Embrex Names Dr. David Shapiro Senior Director, Global Veterinary Services.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters